The company said the kit simplifies the RT-qPCR workflow by eliminating RNA extraction, reducing sample preparation time and limiting the number of handling steps required before gene expression analysis.
The sale transfers a business that develops and supplies microbiology products used across clinical diagnostics, pharmaceutical manufacturing and food safety testing.
Thermo Fisher’s microbiology unit generated US$645 million in revenue in 2025 and operates within the company’s specialty diagnostics segment.